Epidermal Growth Factor (EGFR) copy number aberrations in esophageal and gastro-esophageal junctional carcinoma

BACKGROUND: Clinical trials of agents targeting epidermal growth factor receptor (EGFR) in esophageal carcinoma (EC) have indicated a minority subgroup responsive to anti-EGFR therapies. Other investigations suggest increases in EGFR copy number are associated with poor prognosis in EC, but have use...

Descripción completa

Detalles Bibliográficos
Autores principales: Dahle-Smith, Åsa, Stevenson, David, Massie, Doreen, Murray, Graeme I., Dutton, Susan J., Roberts, Corran, Ferry, David, Osborne, Aileen, Clark, Caroline, Petty, Russell D., Miedzybrodzka, Zosia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609119/
https://www.ncbi.nlm.nih.gov/pubmed/26478746
http://dx.doi.org/10.1186/s13039-015-0181-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609119/
https://www.ncbi.nlm.nih.gov/pubmed/26478746
http://dx.doi.org/10.1186/s13039-015-0181-0

Ejemplares similares